Table 1.
Baseline demographics and disease characteristics.
| Characteristics | N = 107 |
|---|---|
| Age, years, median (range) | 59 (29–80) |
| <65 years, n (%) | 71 (66.4) |
| ECOG performance status 1, n (%) | 48 (44.9) |
| Stage M1 disease, n (%) | 106 (99.1) |
| PD-L1–positive tumor, n (%) | 17 (15.9) |
| Primary site of disease | |
| Pancreas | 40 (37.4) |
| Small intestine | 25 (23.4) |
| Other gastrointestinal | 18 (16.8) |
| Lung | 14 (13.1) |
| Othera | 10 (9.3) |
| Baseline tumor sizeb, mm, median (range) | 139.4 (11.4–370.4) |
| Prior (neo)adjuvant therapy, n (%) | 8 (7.5) |
| No. prior therapies for recurrent/metastatic disease, n (%) | |
| Adjuvant or neoadjuvantc | 2 (1.9) |
| 0d | 4 (3.7) |
| 1 | 25 (23.4) |
| 2 | 33 (30.8) |
| 3 | 12 (11.2) |
| ≥4 | 31 (29.0) |
Note: Data are presented as n (%) unless otherwise noted.
a
Includes anus (n = 1), liver (n = 1), multiple sites (n = 4), ovary (n = 1), and unknown (n = 3).
b
Defined as the sum of the longest diameters of target lesions measurable by central radiology review.
c
Participants received adjuvant/neoadjuvant therapy alone without recurrence.
d
Participants did not receive systemic chemotherapy.